A Phase 1b clinical trial testing pociredir in adults with sickle cell disease has completed enrollment of its high-dose ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy ...
Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...
It is designed to evaluate the safety and tolerability of iadademstat in SCD and to establish the recommended Phase 2 dose (RP2D) as well as to evaluate iadademstat’s effect on inducing fetal ...
Results from a cross-sectional study revealed the gaps in knowledge related to fertility risks among patients with sickle cell disease (SCD), as well as shed light on patient perspectives on fertility ...
The Punch on MSN
SCD and the burden of care – Part 2
In Part 1 of SCD and the burden of care, we explored the emotional, physical, and financial weight that families carry while supporting a loved one living with sickle cell disease.We looked at how ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback